AI drug validation startup Polyphron raises $20M seed from Gradient, Quiet, Compound
darian314 · x · 2026-09-17
Polyphron announced a $20M seed round backed by Gradient, Quiet Capital and Compound, as reported by Axios. Founded by Matthew Osman, the startup builds human tissue models and generation technology to validate AI-created drugs, aiming to get new medicines to market faster and more safely.
More from Venture
- AI-powered language learning platform lists for $7.5M with $137k MRR and 70% margins — marclou · 2026-09-18
- Baylor CIO: capital velocity beats multiple — three 3X funds over 18 years beat one 15X — MartinGTobias · 2026-09-17
- Stripe lays out AI payments stack: Link agent wallet, MPP, tokens and usage billing — jeff_weinstein · 2026-09-17
- An agent workflow for Reddit traffic: review 700 threads, reply to only 15, human approval before posting — mhdfaran · 2026-09-17
- Nebius GPU rate hikes and Fed hikes are connected: AI debt is pushing up yields — kevinsxu · 2026-09-17
- CNBC: OpenAI and Anthropic generate roughly 10x the revenue of all Chinese AI models combined — Polymarket · 2026-09-17